Decoy Therapeutics
DCOY
5 hedge funds and large institutions have $70.8M invested in Decoy Therapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
14% more capital invested
Capital invested by funds: $61.9M → $70.8M (+$8.9M)
61% less call options, than puts
Call options by funds: $183K | Put options by funds: $465K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$169K |
| 2 |
D.E. Shaw & Co
New York
|
-$140K |
| 3 |
Goldman Sachs
New York
|
-$131K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$116K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$114K |
DCOY Hedge Fund Activity: Q3 2016 in Review
5 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2016, worth a combined $70.8M — up 14% from $61.9M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DCOY positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $10.2M. The largest seller was Virtu KCG Holdings, cutting an estimated $169K.
- 5 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2016, up from 4 in Q2 2016.
- Funds reported $70.8M of Decoy Therapeutics stock for Q3 2016, up 14% quarter-over-quarter.
- 1 fund opened new Decoy Therapeutics positions in Q3 2016 and 0 closed out, a net change of +1 holder.
- The largest Decoy Therapeutics buyer in Q3 2016 was Franklin Resources, an estimated $10.2M added.
- The largest Decoy Therapeutics seller in Q3 2016 was Virtu KCG Holdings, an estimated $169K sold.
Based on aggregated 13F filings for Q3 2016.